论文部分内容阅读
目的明确血清CA19-9、CEA及CA125动态变化在胰腺癌同期放化疗患者疗效、预后及随诊中的临床意义。方法采用回顾性分析的方法,通过对本院24例胰腺癌同步放化疗患者血清CA19-9、CEA及CA125治疗前后及治疗期间的动态观察,探讨其变化对临床疗效及预后的关系。结果全组患者中位生存期8.4月;CR4例、PR2例,有效率为25%;治疗前CA19-9≥200 ku/L、CEA≥10μg/L、CA125≥50 ku/L者中位生存期明显短于CA19-9<200 ku/L、CEA<10μg/L、CA125<50 ku/L者,分别为(8.0±1.4)月vs.(15.0±3.7)月,(6.0±1.8)月vs.(12.0±1.7)月,(6.0±1.6)月vs.(12.0±5.6)月(P<0.05或<0.01);在治疗过程中,标志物呈“下降趋势”的患者有12例,中位生存期可达(15.0±3.5)月,有效率为50%;而呈“上升趋势”的12名患者中位生存期仅(6.0±0.6)月,有效率为0,P<0.001;治疗前后若异常血清标志物下降50%可能预测患者预后,中位生存期为(12.0±3.24)月,P<0.05。结论在胰腺癌同期放化疗患者中,血清CA19-9、CA125及CEA联合动态检测,可有效评价治疗效果及预后判断。
Objective To clarify the clinical significance of the dynamic changes of serum CA19-9, CEA and CA125 in the efficacy, prognosis and follow-up of concurrent chemoradiotherapy in patients with pancreatic cancer. Methods The retrospective analysis of 24 patients with pancreatic cancer in patients with concurrent chemoradiotherapy serum CA19-9, CEA and CA125 before and after treatment and dynamic observation during the treatment of its changes on the clinical efficacy and prognosis. Results The median survival time of all the patients was 8.4 months. The CR4 patients and PR2 patients had an effective rate of 25%. Before treatment, patients with CA19-9≥200 ku / L, CEA≥10 μg / L and CA125≥50 ku / L had a median survival (8.0 ± 1.4) months vs (15.0 ± 3.7) months, (6.0 ± 1.8) months, and those with CA19-9 <200 ku / L, CEA <10μg / L and CA125 <50 ku / (12.0 ± 1.7) months, (6.0 ± 1.6) months vs. (12.0 ± 5.6) months (P <0.05 or <0.01). In the course of treatment, there were 12 The median survival time was (15.0 ± 3.5) months and the effective rate was 50%. The median survival time was only 6.0 ± 0.6 months in 12 patients with “up trend”, and the effective rate was 0, P <0.001. A decrease of 50% in abnormal serum markers before and after treatment may predict the prognosis of patients. The median survival time was (12.0 ± 3.24) months, P <0.05. Conclusions In patients with concurrent pancreatic cancer radiotherapy and chemotherapy, serum CA19-9, CA125 and CEA combined dynamic detection, which can effectively evaluate the therapeutic effect and prognosis.